Pfizer's anti-Covid 19 vaccine was purchased by the European Commission despite insufficient testing

The criminal file opened by the Attorney General of the American state of Texas regarding the anti-Covid 19 vaccine manufactured by the Pfizer-BioNTech consortium may also have an influence on the investigation that the European Public Prosecutor's Office is conducting related to the purchase of vaccines during the pandemic, a negotiated and concluded joint purchase for the EU member states by the European Commission, more precisely by Ursula von der Leyen, the president of the Brussels Commission.

Following the announcement made in September 2022 by the European Public Prosecutor's Office regarding the opening of the criminal case in rem (on the facts) regarding the purchase of anti-Covid 19 vaccines, on October 10, 2022, during its hearing before the special committee of the European Parliament, Janine Small, head of Pfizer's International Sales Department, admitted that the anti-Covid vaccine has never been tested to prevent the transmission of this virus.

Small's response is noted in material published last year by the Associated Press News: "When asked by MEP Rob Ross (Netherlands/Netherlands) whether Pfizer tested its vaccine against COVID-19 for its ability to prevent the transmission of the virus before its release on the market, Small replied: «No. Science had to move quickly to really understand what was happening in the market». She went on to explain why Pfizer has moved quickly to develop a COVID-19 vaccine as the virus spreads around the world. While Roos and many others framed this as a new revelation, Pfizer never claimed that its clinical trial, on the basis of which the vaccine was approved for use, assessed the vaccine's effect on transmission. In fact, shortly before the vaccine was released, the company's CEO emphasized that this was still under evaluation."

The cited source also says that a study funded by Pfizer and German vaccine maker BioNTech, published in the New England Journal of Medicine on December 10, 2020, a day before the Food and Drug Administration (FDA) gave emergency use authorization of Pfizer's COVID-19 vaccine, did not include data on the vaccine's effectiveness in reducing transmission of the virus.

Instead, it reported that two doses of the vaccine provided 95% protection against contracting symptomatic COVID-19 in people 16 years and older.

According to AP News, Pfizer CEO Albert Bourla also said in a December 2020 interview with NBC News that it was not yet clear whether vaccinated people could transmit the virus and pass it on to others.

"I think this is something that needs to be looked into. We're not sure about that right now," he told NBC News.

Furthermore, in the December 11, 2020 press release announcing the approval of Pfizer's Covid-19 vaccine, FDA officials claimed that "at this time, no data are available to determine how long the vaccine will provide protection, nor is there evidence that the vaccine prevents the transmission of Sars-Cov-2 from one person to another".

The Associated Press also mentions that a Pfizer spokesperson told the news agency that the company's clinical trial was designed to evaluate the effectiveness of the Covid-19 vaccine in preventing disease caused by the Sars-Cov-2 virus, including severe disease.

"Stopping transmission was not an endpoint of the study," a Pfizer spokesperson told AP News in an email.

Under these circumstances, it seems incomprehensible the decision of the president of the European Commission, Ursula von der Leyen, who imposed the purchase of these vaccines, as long as they had not been sufficiently tested and there were no data either on the prevention of the transmissibility of the virus, or on the number doses needed for a single person.

In relation to this aspect, the US Center for Disease Control and Prevention (CDC) specifies in a report published on August 19, 2022, that receiving only one or two doses of the Covid-19 vaccine "provides minimal protection against infection and transmission " and that in the case of booster doses one can only speak of "a transitory period of increased protection against infection and transmission after the most recent dose, as protection declines over time".

The cited source states that Dr. Paul Offit, a member of the FDA's Vaccines and Related Biological Products Advisory Committee, explained that while vaccines provide neutralizing antibodies, which help protect against infection, these types of antibodies decline rapidly -- even if the protection against serious diseases continues to last.

Offit added that the messages sent by authorities to citizens about vaccines were wrong and should have stopped awake to their main benefit - prevention of serious illness and hospitalization - as many would later question the success of vaccines due to "breakthrough infections".

We remind you that for December 2020 the European Commission ordered 200 million doses of vaccine from Pfizer, with an option for another 100 million doses, and in the spring of 2021 concluded a contract with the American company - negotiated, according to the American media, through WhatsApp messages by Ursula von der Leyen with Albert Bourla, CEO of Pfizer - for another 2.4 billion doses, out of the total 4.2 billion doses of the anti-Covid 19 vaccine ordered from the eight international manufacturers.

In relation to the purchase of vaccines, we also mention that on November 23 DNA requested the approval of the prosecution of former prime minister Florin Cîţu, and of the ministers of health Vlad Voiculescu and Ioana Mihăilă for abuse of office. The anti-corruption prosecutors claim that in 2021 the three ordered the additional purchase of more than 52 million doses of vaccine, although there were still enough doses in the stocks in the warehouses, without any technical evaluation, which caused a damage of more than one billion euros the state budget. President Klaus Iohannis approved on November 27 the DNA request for criminal prosecution for former ministers Voiculescu and Mihăilă, and the Senate approved on November 29 the lifting of the parliamentary immunity of Florin Cîţu, so that he could be prosecuted.